Vivici BV and Ginkgo Bioworks announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo’s extensive capabilities in strain engineering, optimization and performance, to develop and commercialize a next generation of functional alternative protein.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks downgraded to Market Perform yesterday at Raymond James
- Ginkgo Bioworks downgraded to Market Perform from Outperform at Raymond James
- Cathie Wood’s ARK Investment bought 515K shares of Ginkgo Bioworks today
- Tesla initiated, Kellanova upgraded: Wall Street’s top analyst calls
- Ginkgo Bioworks price target lowered to $7 from $12 at TD Cowen